The EVP & GC of Ardelyx (ARDX) is Selling Shares


Today, the EVP & GC of Ardelyx (ARDX), Elizabeth Grammer, sold shares of ARDX for $18.57K.

In addition to Elizabeth Grammer, 2 other ARDX executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ardelyx’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $172K and GAAP net loss of $24.13 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $20.72 million. Currently, Ardelyx has an average volume of 182K.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts